Philip Morris International Names New External Affairs Leader
26.3.2024 12:48:00 EET | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company’s CEO, Jacek Olczak.
“Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products,” said CEO Jacek Olczak. “He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I’m looking forward to working with Christos and excited to see what opportunities we can unlock as he takes the helm of our External Affairs function globally.”
Since joining PMI in 2003, Mr. Harpantidis has held several positions, including setting the commercialization strategy for smoke-free products in Lausanne, Switzerland, and serving as Chairman and Managing Director of Papastratos in Greece. Most recently, he served as Area Vice President of the South East Europe Area. Throughout his career at PMI, he has strongly contributed to growing the company’s smoke-free consumer base, expanding its brand portfolio, and advocating for regulations consistent with PMI’s smoke-free ambitions. Prior to joining the company, he worked at Coca-Cola Hellenic. Mr. Harpantidis holds a degree in physics from the Aristotle University of Thessaloniki, Greece, as well as master’s degrees in economics and business administration from Kent University in the United Kingdom.
“Leading our dynamic External Affairs function globally is an enormous honor,” said Christos Harpantidis. “I look forward to building on the remarkable progress already achieved by the team, which is resulting in science-based tobacco harm reduction policies being endorsed by more countries. I am incredibly proud of the work we are doing to transform our company and of the way civil society is coming together to support us. Still, more must be done. To realize our world-changing vision, we must continue to engage in transparent dialogue, build trust in the evidence, and work closely with policymakers and public health stakeholders to accelerate change.”
This appointment follows the decision of Grégoire Verdeaux to leave PMI at the end of April to pursue other professional opportunities. During his tenure, Mr. Verdeaux expanded the company’s global tobacco harm reduction strategy and, with the team, built compelling policy positions and advocated for regulations consistent with our smoke-free ambitions.
“Thanks, in large part, to Grégoire’s efforts, tobacco harm reduction policies are now endorsed by a growing number of countries,” said Mr. Olczak. “Under Christos’ leadership, I believe that the External Affairs function will ensure that this positive momentum is maintained and further amplified.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested $12.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products. As of December 31, 2023, PMI’s smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 20.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 37 percent of PMI’s total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326602014/en/
Contact information
Philip Morris International
David Fraser
T. +41 (0)58 242 4500
E. David.Fraser@pmi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 10:01:00 EEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
IQM Launches HPC Integration Service to Accelerate Hybrid Quantum-HPC Adoption12.5.2026 10:00:00 EEST | Press release
IQM Quantum Computers today launched HPC Integration Service, a turnkey solution that enables its IQM Radiance quantum computers to operate as a slurm node inside high-performance computing (HPC) environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512187465/en/ IQM Radiance quantum computer (right) co-located with classical HPC infrastructure (left) in a data center environment. Using this widely adopted HPC workflow, IQM aims at accelerating adoption of hybrid quantum-classical computing across enterprises and research institutions. Slurm is the open-source workload manager used by most of the world’s leading supercomputing centers for its scalability and flexibility. The integration service makes quantum a scheduled resource alongside central processing units (CPUs) and graphics processing units (GPUs), removing the integration work that has slowed adoption. In addition, the service is built on IQM´s Quantum Dev
Visa Flexible Credential Brings More Flexible Ways to Pay to Zilch Cardholders in the UK12.5.2026 10:00:00 EEST | Press release
Visa, a world leader in digital payments, Zilch and Thredd today announced the introduction of Visa Flexible Credential (VFC) on Zilch cards in the UK, enabling more flexible ways to pay through a single, familiar card experience. Demand for flexible payment experiences continues to grow. Many people no longer think in fixed terms such as debit or credit, instead wanting the ability to choose what works best for a specific purchase in the moment. In the UK, 87% of people surveyed say flexible payment options support their financial or lifestyle goals1. Visa Flexible Credential is designed to support this shift, helping issuers offer more choice through one familiar card that already works at more than 150 million merchant locations worldwide. The new capability allows different payment options to sit behind one card or digital credential, giving cardholders greater choice and control while preserving the familiarity of tapping or paying as they always have. Visa Flexible Credential is
AMP IT Announces New Funding Round to Scale Its Private EV Charging as a Service in Switzerland and Beyond12.5.2026 09:43:00 EEST | Press release
AMP IT, a Geneva-based energy and mobility company, today announced the successful completion of a new funding round to accelerate the deployment of its private EV charging and energy management platform across Switzerland and international markets. Founded in 2021, AMP IT develops, finances, installs, and operates smart EV charging infrastructure for residential buildings, commercial real estate, and corporate fleets. Through its charging-as-a-service model, the company combines infrastructure with its proprietary software, AMP IT Hub, delivering a fully integrated energy solution. The latest funding round, supported notably by the Swiss Technology Fund, brings AMP IT’s total funding to €7 million since inception. The capital will support operational scaling, further development of its software platform, and expansion into selected European markets. “Users are increasingly looking for solutions that are simple, efficient, and affordable which is exactly what we provide,” said Florian
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 09:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-CM that is designed to deliver rapid knockdown of TTR at the source. The data presented at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology, show consistent clinical benefit across patient populations commonly encountered in clinical practice, including those with a high disease burden, supporting its use as a first-line treatment option for this rapidly progressive and life-threatening disease. “The analyses presented at Heart Failu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
